Ertumaxomab
Jump to navigation
Jump to search
Template:Short description Template:Cs1 config Template:Drugbox Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.
It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.[1][2]
Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.[3] (So they could concentrate on their other product catumaxomab (trade name Removab).[4]Template:Rp)
References
<templatestyles src="Reflist/styles.css" />
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Clinical trial number NCT00522457 for "Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy " at ClinicalTrials.gov
- ↑ Script error: No such module "citation/CS1".
Script error: No such module "Check for unknown parameters".
Template:Monoclonals for tumors
Template:Growth factor receptor modulators